• Explore /
  • Poster
  • / Pre-existing interstitial lung abnormalities are independent risk factors for interstitial lung disease during durvalumab treatment after chemoradiotherapy in patients with locally advanced non–small lung cancer.

Pre-existing interstitial lung abnormalities are independent risk factors for interstitial lung disease during durvalumab treatment after chemoradiotherapy in patients with locally advanced non–small lung cancer.

Abstract Video & Slides Poster

Authors

null

Wakako Daido

Department of Respiratory Medicine, Hiroshima University Hospital, Hiroshima, Japan

Wakako Daido , Takeshi Masuda , Nobuki Imano , Naoko Matsumoto , Hiroyasu Shoda , Kosuke Hamai , Yasuo Iwamoto , Yusuke Takayama , Shohei Mishima , Ken Masuda , Shigeo Kawase , Yoshikazu Awaya , Yoshifumi Nishimura , Naoki Shiota , Nobuhisa Ishikawa , Masahiro Yamasaki , Soichi Kitaguchi , Kazunori Fujitaka , Yasushi Nagata , Noboru Hattori

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

Track

Lung Cancer

Sub Track

Biologic Correlates

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 8528)

DOI

10.1200/JCO.2022.40.16_suppl.8528

Abstract #

8528

Poster Bd #

155

Abstract Disclosures

Similar Posters

First Author: Chloe Lim

First Author: Jarushka Naidoo

First Author: Lian Liu

First Author: John M. Varlotto